{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:54:48Z","timestamp":1790362488858,"version":"4.1.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016156","name":"US Army Medical Research and Development Command","doi-asserted-by":"publisher","award":["W81XWH-17-2-0043"],"award-info":[{"award-number":["W81XWH-17-2-0043"]}],"id":[{"id":"10.13039\/100016156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["T32 CA009515"],"award-info":[{"award-number":["T32 CA009515"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R37 CA268450"],"award-info":[{"award-number":["R37 CA268450"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA097186-21"],"award-info":[{"award-number":["P50 CA097186-21"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.urolonc.2026.07.014","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:44:46Z","timestamp":1785786286000},"page":"671-682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Beyond androgen deprivation therapy: Next-generation hormonal therapies and emerging combination approaches in advanced prostate cancer"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2148-283X","authenticated-orcid":false,"given":"Gabrielle","family":"Paras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.urolonc.2026.07.014_bib0001","first-page":"S3","article-title":"Androgen deprivation therapy in the treatment of advanced prostate cancer","volume":"9","author":"Perlmutter","year":"2007","journal-title":"Rev Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.07.014_bib0002","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jamaoncol.2015.4917","article-title":"Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy","volume":"2","author":"Sun","year":"2016","journal-title":"JAMA Oncol"},{"issue":"5151","key":"10.1016\/j.urolonc.2026.07.014_bib0003","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/219277a0","article-title":"Selective retention of dihydrotestosterone by prostatic nuclei","volume":"219","author":"Anderson","year":"1968","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.urolonc.2026.07.014_bib0004","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.1016\/S0021-9258(18)94513-8","article-title":"The intranuclear binding of testosterone and 5-alpha-androstan-17-beta-ol-3-one by rat prostate","volume":"243","author":"Bruchovsky","year":"1968","journal-title":"J Biol Chem"},{"issue":"21","key":"10.1016\/j.urolonc.2026.07.014_bib0005","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and Increased Survival in Metastatic Prostate Cancer","volume":"364","author":"Bono","year":"2011","journal-title":"N Eng J Med"},{"issue":"13","key":"10.1016\/j.urolonc.2026.07.014_bib0006","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2026.07.014_bib0007","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.014_bib0008","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.urolonc.2026.07.014_bib0009","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.urolonc.2026.07.014_bib0010","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0092-8674(95)90199-X","article-title":"The nuclear receptor superfamily: the second decade","volume":"83","author":"Mangelsdorf","year":"1995","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.urolonc.2026.07.014_bib0011","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0960-0760(97)00049-6","article-title":"Localization of functional domains in the androgen receptor","volume":"62","author":"MacLean","year":"1997","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"10","key":"10.1016\/j.urolonc.2026.07.014_bib0012","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrclinonc.2011.117","article-title":"The changing therapeutic landscape of castration-resistant prostate cancer","volume":"8","author":"Yap","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.07.014_bib0013","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/aja202494","article-title":"Androgen receptor inhibitors in treating prostate cancer","volume":"27","author":"Cole","year":"2025","journal-title":"Asian J Androl"},{"issue":"7","key":"10.1016\/j.urolonc.2026.07.014_bib0014","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1172\/JCI66398","article-title":"An androgen receptor N-terminal domain antagonist for treating prostate cancer","volume":"123","author":"Myung","year":"2013","journal-title":"J Clin Invest"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2026.07.014_bib0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1200\/JCO.2023.41.6_suppl.179","article-title":"Phase 1\/2 study of EPI-7386 in combination with enzalutamide (enz) compared with enz alone in subjects with metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Laccetti","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.014_bib0016","unstructured":"ESSA Pharma announces termination of phase 2 study evaluating masofaniten combined with enzalutamide in patients with metastatic castration-resistant prostate cancer. News release. ESSA Pharma Inc.October 31, 2024.Accessed September 23, 2025.https:\/\/investors.essapharma.com\/2024-10-31-ESSA-Pharma-Announces-Termination-of-Phase-2-Study-Evaluating-Masofaniten-Combined-with-Enzalutamide-in-Patients-with-Metastatic-Castration-Resistant-Prostate-Cancer."},{"issue":"38","key":"10.1016\/j.urolonc.2026.07.014_bib0017","doi-asserted-by":"crossref","first-page":"26417","DOI":"10.1074\/jbc.M114.553818","article-title":"Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer","volume":"289","author":"Dalal","year":"2014","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.urolonc.2026.07.014_bib0018","doi-asserted-by":"crossref","first-page":"12496","DOI":"10.3390\/ijms140612496","article-title":"Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer","volume":"14","author":"Lallous","year":"2013","journal-title":"Int J Mol Sci"},{"issue":"15","key":"10.1016\/j.urolonc.2026.07.014_bib0019","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1093\/emboj\/cdf406","article-title":"Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase","volume":"21","author":"Lin","year":"2002","journal-title":"EMBO J"},{"issue":"5","key":"10.1016\/j.urolonc.2026.07.014_bib0020","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat Chem Biol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.07.014_bib0021","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nature Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.014_bib0022","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s42003-018-0105-8","article-title":"Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance","volume":"1","author":"Salami","year":"2018","journal-title":"Comm Biol"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2026.07.014_bib0023","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1200\/JCO.2020.38.15_suppl.3500","article-title":"First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and\/or abiraterone (ABI)","volume":"38","author":"Petrylak","year":"2020","journal-title":"J Clin Oncol."},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2026.07.014_bib0024","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.2022.40.6_suppl.017","article-title":"Phase 1\/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Gao","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.07.014_bib0025","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1200\/JCO.2024.42.16_suppl.5011","article-title":"ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1\/2 study","volume":"42","author":"Petrylak","year":"2024","journal-title":"Journal of Clinical Oncology."},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.014_bib0026","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.annonc.2024.09.005","article-title":"Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer","volume":"36","author":"Rathkopf","year":"2025","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.07.014_bib0027","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5119","article-title":"A phase 3 trial of the androgen receptor ligand-directed degrader, BMS-986365, versus investigator&rsquo;s choice in patients with metastatic castration-resistant prostate cancer (CA071-1000 - rechARge)","volume":"43","author":"Chi","year":"2025","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.urolonc.2026.07.014_bib0028","article-title":"Prevalence and Spectrum of AR Ligand-Binding Domain Mutations Detected in Circulating-Tumor DNA Across Disease States in Men With Metastatic Castration-Resistant Prostate Cancer","volume":"8","author":"Antonarakis","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.07.014_bib0029","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/cancers16030663","article-title":"Insight into recent advances in degrading androgen receptor for castration-resistant prostate cancer","volume":"16","author":"Chen","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.urolonc.2026.07.014_bib0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/1521-4184(200204)335:4<119::AID-ARDP119>3.0.CO;2-#","article-title":"Inhibition of CYP 17, a new strategy for the treatment of prostate cancer","volume":"335","author":"Hartmann","year":"2002","journal-title":"Arch Pharm (Weinheim)"},{"issue":"4","key":"10.1016\/j.urolonc.2026.07.014_bib0031","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/j.2040-4603.2014.tb00590.x","article-title":"Adrenal androgens and androgen precursors-definition, synthesis, regulation and physiologic actions","volume":"4","author":"Turcu","year":"2014","journal-title":"Compr Physiol"},{"issue":"11","key":"10.1016\/j.urolonc.2026.07.014_bib0032","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res"},{"issue":"28","key":"10.1016\/j.urolonc.2026.07.014_bib0033","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2026.07.014_bib0034","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1158\/1535-7163.MCT-22-0115","article-title":"First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis","volume":"21","author":"Karimaa","year":"2022","journal-title":"Mole Canc Thera"},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.014_bib0035","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300171","article-title":"Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer","volume":"3","author":"Fizazi","year":"2024","journal-title":"NEJM Evid"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.07.014_bib0036","article-title":"CYP11A1 inhibitor MK-5684 versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after NHA and taxane-based chemotherapy: Phase 3 MK-5684-003 trial","volume":"42","author":"Yu","year":"2024","journal-title":"J Clin Oncol."},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.07.014_bib0037","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5114","article-title":"CYP11A1 inhibitor MK-5684 versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after 1 prior NHA: Phase 3 MK-5684-004 study","volume":"4","author":"Fizazi","year":"2024","journal-title":"J Clin Oncol."},{"issue":"8_Supplement_1","key":"10.1016\/j.urolonc.2026.07.014_bib0038","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/1538-7445.AM2025-1777","article-title":"Abstract 1777: OST11098, an orally available and selective Cyp11A1 inhibitor for the treatment of castration-resistant prostate cancer (CRPC) with next-generation hormone agents (NHAs) resistance","volume":"85","author":"Wu","year":"2025","journal-title":"Can Res."},{"issue":"8_Supplement_1","key":"10.1016\/j.urolonc.2026.07.014_bib0039","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1158\/1538-7445.AM2025-6881","article-title":"Abstract 6881: Discovery of ACE-232: a novel and highly potent non-steroidal CYP11A1 inhibitor","volume":"85","author":"Yu","year":"2025","journal-title":"Canc Res."},{"issue":"5","key":"10.1016\/j.urolonc.2026.07.014_bib0040","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2026.07.014_bib0041","doi-asserted-by":"crossref","first-page":"113249","DOI":"10.1016\/j.ejca.2023.113249","article-title":"The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer","volume":"192","author":"Agarwal","year":"2023","journal-title":"Euro J Canc"},{"issue":"22","key":"10.1016\/j.urolonc.2026.07.014_bib0042","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.urolonc.2026.07.014_bib0043","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or Physician\u2019s Choice in Metastatic Prostate Cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2026.07.014_bib0044","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","article-title":"The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings","volume":"5","author":"Helleday","year":"2011","journal-title":"Mol Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2026.07.014_bib0045","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","article-title":"Dual roles of PARP-1 promote cancer growth and progression","volume":"2","author":"Schiewer","year":"2012","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.014_bib0046","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41391-022-00636-0","article-title":"Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer","volume":"26","author":"Schweizer","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.014_bib0047","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","article-title":"Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer","volume":"8","author":"Asim","year":"2017","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.urolonc.2026.07.014_bib0048","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evidence"},{"issue":"10","key":"10.1016\/j.urolonc.2026.07.014_bib0049","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.urolonc.2026.07.014_bib0050","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2026.07.014_bib0051","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"issue":"10398","key":"10.1016\/j.urolonc.2026.07.014_bib0052","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.014_bib0053","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nat Med"},{"issue":"10502","key":"10.1016\/j.urolonc.2026.07.014_bib0054","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(25)00683-X","article-title":"Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Fizazi","year":"2025","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.urolonc.2026.07.014_bib0055","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1200\/JCO.23.02105","article-title":"Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer A US Food and Drug Administration Pooled Analysis","volume":"42","author":"Fallah","year":"2024","journal-title":"J Clin Oncol."},{"issue":"12","key":"10.1016\/j.urolonc.2026.07.014_bib0056","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1038\/s41591-025-03961-8","article-title":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","volume":"31","author":"Attard","year":"2025","journal-title":"Nat Med"},{"issue":"17_suppl","key":"10.1016\/j.urolonc.2026.07.014_bib0057","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA5007","article-title":"TALAPRO-3: Talazoparib (TALA)\u202f+\u202fenzalutamide (ENZA) compared with placebo (PBO)\u202f+\u202fENZA for the treatment of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) harboring homologous recombination repair (HRR) gene alterations","volume":"44","author":"Agarwal","year":"2026","journal-title":"J Clin Oncol."},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.07.014_bib0058","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.8621","volume":"42","author":"Chi","year":"2024","journal-title":"J Clin Oncol."},{"issue":"4","key":"10.1016\/j.urolonc.2026.07.014_bib0059","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrurol.2018.9","article-title":"Clinical implications of PTEN loss in prostate cancer","volume":"15","author":"Jamaspishvili","year":"2018","journal-title":"Nat Rev Urol"},{"issue":"10295","key":"10.1016\/j.urolonc.2026.07.014_bib0060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.urolonc.2026.07.014_bib0061","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.eururo.2024.12.015","article-title":"Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial","volume":"87","author":"de Bono","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.07.014_bib0062","unstructured":"AstraZeneca. Update on CAPItello-280 phase III trial of Truqap in metastatic castration-resistant prostate cancer. News release. AstraZeneca. 2025. Accessed September 29, 2025. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/update-on-capitello-280-phase-iii-trial.html."},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.014_bib0063","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.annonc.2025.10.004","article-title":"Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study","volume":"37","author":"Fizazi","year":"2026","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.07.014_bib0064","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","article-title":"N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer","volume":"30","author":"Dardenne","year":"2016","journal-title":"Canc Cell"},{"issue":"5_suppl","key":"10.1016\/j.urolonc.2026.07.014_bib0065","article-title":"Mevrometostat (PF-06821497), an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): A randomized dose-expansion study","volume":"43","author":"Schweizer","year":"2025","journal-title":"J Clin Oncol."},{"issue":"5_suppl","key":"10.1016\/j.urolonc.2026.07.014_bib0066","article-title":"Mevrometostat (PF-06821497) in combination with enzalutamide for androgen receptor pathway inhibitor (ARPI)-na&iuml;ve patients with metastatic castration-resistant prostate cancer (mCRPC): The phase 3, randomized MEVPRO-2 trial","volume":"43","author":"Schweizer","year":"2025","journal-title":"J Clin Oncol."},{"issue":"5_suppl","key":"10.1016\/j.urolonc.2026.07.014_bib0067","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS288","article-title":"Mevrometostat (PF-06821497) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate: The phase 3, randomized MEVPRO-1 study","volume":"43","author":"Agarwal","year":"2025","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.urolonc.2026.07.014_bib0068","doi-asserted-by":"crossref","first-page":"S967","DOI":"10.1016\/j.annonc.2024.08.1684","article-title":"1603P Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"35","author":"Abida","year":"2024","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.urolonc.2026.07.014_bib0069","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-17-3571","article-title":"Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)","volume":"24","author":"Welti","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"7504","key":"10.1016\/j.urolonc.2026.07.014_bib0070","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nature13229","article-title":"Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer","volume":"510","author":"Asangani","year":"2014","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.urolonc.2026.07.014_bib0071","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1158\/1078-0432.CCR-20-1707","article-title":"A Phase Ib\/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer","volume":"26","author":"Aggarwal","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.urolonc.2026.07.014_bib0072","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-22-0175","article-title":"Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer","volume":"28","author":"Aggarwal","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.urolonc.2026.07.014_bib0073","first-page":"293","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate*","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.urolonc.2026.07.014_bib0074","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/1097-0142(196711)20:11<1871::AID-CNCR2820201112>3.0.CO;2-D","article-title":"Response of men with advanced prostatic carcinoma to exogenous administration of testosterone","volume":"20","author":"Prout","year":"1967","journal-title":"Cancer"},{"issue":"26","key":"10.1016\/j.urolonc.2026.07.014_bib0075","doi-asserted-by":"crossref","first-page":"15152","DOI":"10.1073\/pnas.93.26.15152","article-title":"Androgen-repressed phenotype in human prostate cancer","volume":"93","author":"Zhau","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.urolonc.2026.07.014_bib0076","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1423-0127-18-63","article-title":"Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer","volume":"18","author":"Chuu","year":"2011","journal-title":"J Biomed Sci"},{"issue":"8","key":"10.1016\/j.urolonc.2026.07.014_bib0077","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.613","article-title":"Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements","volume":"42","author":"Haffner","year":"2010","journal-title":"Nat Genet"},{"issue":"269","key":"10.1016\/j.urolonc.2026.07.014_bib0078","doi-asserted-by":"crossref","first-page":"269ra2","DOI":"10.1126\/scitranslmed.3010563","article-title":"Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study","volume":"7","author":"Schweizer","year":"2015","journal-title":"Sci Transl Med"},{"issue":"14","key":"10.1016\/j.urolonc.2026.07.014_bib0079","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/pros.21196","article-title":"Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen\/ablation in men with castration resistant prostate cancer","volume":"70","author":"Denmeade","year":"2010","journal-title":"Prostate"},{"issue":"10","key":"10.1016\/j.urolonc.2026.07.014_bib0080","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1172\/JCI127613","article-title":"Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage","volume":"129","author":"Chatterjee","year":"2019","journal-title":"J Clin Invest"},{"issue":"13","key":"10.1016\/j.urolonc.2026.07.014_bib0081","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1158\/1078-0432.CCR-15-1147","article-title":"Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation","volume":"22","author":"Hedayati","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.urolonc.2026.07.014_bib0082","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.20.02759","article-title":"A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer","volume":"39","author":"Denmeade","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:11:21Z","timestamp":1789758681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":82,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1078143926005995"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.014","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond androgen deprivation therapy: Next-generation hormonal therapies and emerging combination approaches in advanced prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}